results from the ongoing phase 1 clinical trial in non-Hodgkin's
Lymphoma at the 10th International Conference on Malignant Lymphoma,
Lugano, Switzerland.
-- Also in the second quarter, Micromet expects to initiate IND-enabling
toxicology studies with MT203 in its collaboration with Nycomed.
-- A phase 1 clinical trial evaluating MT103 in patients with chronic
lymphocytic leukemia is expected to be started in the United States by
Micromet's collaboration partner MedImmune. In addition, at the
conference of the American Society of Hematology (ASH) in December 2008,
Micromet anticipates providing an update on the clinical data of the
ongoing clinical trials with MT103.
-- Micromet plans to initiate a phase 2 clinical trial to evaluate
adecatumumab (MT201) in an adjuvant setting. In addition, first data
from the ongoing phase 1b combination trial of adecatumumab with
docetaxel are expected to be presented in the second half of 2008.
Conference Call and Audio Webcast Today, May 8, 2008, at 9:00 am Eastern Time
To participate in this conference call, dial 800-901-5218 (U.S.) or 617-786-4511 (international), passcode: 79417745. The audio webcast can be accessed at: http://www.micromet-inc.com in the investor relations section of the website.
A replay of the call will be available from 11:00 am Eastern Time on May 8, 2008 (5:00 pm Central European Time) through Thursday, May 15, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 99810027.
About Micromet, Inc. (http://www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation an
'/>"/>
| SOURCE Micromet, Inc. Copyright©2008 PR Newswire. All rights reserved |